account_id none on file
legal_name Tyra Biosciences, Inc.
ticker TYRA
cik 1863127
domain tyra.bio
linkedin_company_url https://www.linkedin.com/company/tyra-biosciences/
entry_point_account_id none on file
name Tyra Biosciences Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 4 executives 2 family 0
why_nownone on file
callsnone on file
filings
The remaining increase was driven by a $6.5 million increase in personnel-related expenses primarily due to headcount growth to support expanding clinical and development activities and a $0.5 million increase in facilities and other costs.
filing / Aug 4, 2026 / receipt
The increase of $2.7 million was primarily related to higher compensation and other personnel expenses, including an increase in non-cash stock-based compensation costs of $1.8 million, driven by headcount growth.
filing / Aug 4, 2026 / receipt
Personnel-related expenses also increased by $3.8 million, driven by headcount growth to support expanding clinical and development activities.
filing / May 13, 2026 / receipt
The increase of $1.6 million was primarily related to higher compensation and other personnel expenses, including an increase in non-cash stock-based compensation costs of $0.6 million, driven by headcount growth.
filing / May 13, 2026 / receipt
executives
| Adele M. Gulfo | director | - | receipt |
| Bhavesh Ashar | Chief Operating Officer | - | receipt |
familynone on file
upcoming
| 2026-11-04 | earnings call | scheduled | ir |
changes
mcp_package_hint
slug tyra-biosciences-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$